Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort

Key Points

• Ocrelizumab shows a greater impact on reducing smoldering activity compared to teriflunomide, suggesting different therapeutic benefits.
• Participants in the study showed varied responses to both drugs, emphasizing the importance of personalized treatment approaches.
• Observational study utilizing data from the Swiss Multiple Sclerosis Cohort to assess treatment effectiveness across different cases.
• Significant findings support the need for further exploration into the efficacy of these treatments in diverse populations.